Compare Gilead Sciences, Inc. (GILD) vs Honest Company Inc (HNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Honest Company Inc — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Honest Company Inc trades at $5.07 (market cap $533.20M). The key difference: Gilead Sciences, Inc. is far larger — about 342.1× Honest Company Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Honest Company Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Honest Company Inc for 39 Days on average.
| GILD | HNST | |
|---|---|---|
Market Cap | $182.40B | $533.20M |
Volume | 4,469,821 | 1,990,155 |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $5.95 |
52-Week Low | $117.18 | $2.10 |
Typical Hold Time | 111 Days | 39 Days |
Enterprise Value | $205.46B | $436.81M |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
HNST trades at $4.97, up 0.81% with a bearish technical outlook despite recent institutional buying. The company shows mixed fundamentals with Q2 2026 earnings beating estimates but negative profit margins and declining revenue guidance for 2026. Analyst consensus is cautious with a $5.30 price target and 30% buy rating distribution.
The stock faces headwinds from negative profitability and competitive pressures, though strategic exits show early turnaround signs. Upside potential exists if margin improvements continue, but investors should weigh execution risks against institutional accumulation trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →
